High-throughput optical assay of human mixed cell population spheroids

Three-dimensional spheroids in FLIPR systems address the inconsistency of two-dimensional cell assays by providing consistent drug response data, enabling high-throughput screening and disease modeling.

JP2024160334APending Publication Date: 2024-11-13AXOSIM INC
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
JP2024134146
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-07-14
Filing Date
2024-08-09
Publication Date
2024-11-13

AI Technical Summary

Technical Problem

Automating high-throughput assays using living human cells is challenging, particularly in fluorescence imaging plate readers (FLIPR) due to inconsistent data generation from non-uniform cell attachment in two-dimensional formats, which affects drug interaction and pharmacokinetic data consistency.

Method used

Utilizing three-dimensional (3D) spheroids of mixed human cell populations, such as neuronal spheroids, cultured for weeks to establish a robust synaptic network, and performing optical assays with FLIPR to monitor calcium oscillations and drug interactions, ensuring consistent data generation.

Benefits of technology

The 3D spheroids provide predictable and consistent drug response data, enabling high-throughput screening for drug interactions and pharmacokinetic analysis, mimicking mature brain function and potential applications in disease models like epileptic seizures.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024160334000001_ABST
    Figure 2024160334000001_ABST
Patent Text Reader

Abstract

To provide a method of performing functional in vitro assays using living human cells.SOLUTION: The present disclosure provides a method of performing a functional assay on human spheroids such as three-dimensional human cell spheroids using, in one embodiment, a fluorometric imaging plate reader.SELECTED DRAWING: Figure 4
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of the filing date of U.S. Application No. 62 / 532,667, filed July 14, 2017, the disclosure of which is incorporated herein by reference. [Background technology]

[0002] background The accelerating pace of drug discovery has led to an increasing need for functional in vitro assays using live human cells. However, automating these assays for high-throughput systems has proven difficult. It is noted that the most common biological assays used in high-throughput settings rely on some type of fluorescence measurement.

[0003] The Fluorescence Imaging Plate Reader, also known as FLIPR, is a unique combination of optics, automated pipetting, and temperature control. FLIPR is designed to perform high-throughput screening assays using adherent and non-adherent cells and is ideal for dynamic cell-based assays such as measuring changes in intracellular calcium levels or membrane potential.

[0004] FLIPR integrates a powerful argon laser, a CCD (charge-coupled device) imaging camera, an optical detection scheme, and a programmable 96-well pipetter to simultaneously perform fluorescence analysis of all 96 wells of a microplate. The system generates real-time kinetic data by stimulating and reading all 96 wells at 1-second intervals. Typically, an argon laser excites an appropriate fluorescent dye. The resulting emitted light is detected by a cooled CCD camera that acts as an integrated detector, accumulating the signal over the period of exposure. Sensitivity is further enhanced by the FLIPR optical scheme, which limits the depth of field of the CCD camera to a few hundred microns at the bottom of each well, or essentially at the level of the cell monolayer. This approach reduces background fluorescence from extracellular dyes by about an order of magnitude. Taken together, these systems are integrated into a highly sensitive fluorescence detector.

[0005] The FLIPR instrument captures real-time kinetic data, enabling the identification of potential drug hits within seconds of their addition to the assay. Indeed, one of the hallmarks of FLIPR technology is data fidelity, allowing researchers to monitor single-well measurements. The software also performs data analysis and reduction, and can export data to a spreadsheet program.

[0006] Use of the FLIPR with 2D cell formats, where cells of interest are added to microplate wells and form a monolayer across the well bottom, has proven problematic because cells do not always fill the wells uniformly or attach with high fidelity. This leads to the generation of inconsistent data measured by the FLIPR within and between plates. When performing high throughput screens in 96, 384 or 1536 well plates, data consistency is necessary to generate meaningful information regarding drug interactions or pharmacokinetic data. Summary of the Invention

[0007] overview Surprisingly, modulation of calcium oscillations by drug molecules on 3D spheroids can be monitored and the resulting data is highly consistent. For example, spheroid neuronal synapses are predictably and consistently excited over long periods of time. In one embodiment, the present disclosure provides optical assays, such as functional FLIPR assays or high content high magnification optical microscopy, of 3D human cell spheroids, such as mixed population human cell neuronal spheroids. In one embodiment, prior to testing, spheroids are cultured for 4-16 weeks to induce robust synchronous synaptic networks to mimic mature human-like brain function. These mixed population spheroids are predictably and consistently excited over long periods of time. In one embodiment, the present disclosure provides high throughput optical assays of mixed populations of human cell 3D spheroids utilizing FLIPR and calcium uptake fluorescence oscillations. Oscillations can be tuned with chemical compounds and oscillatory excitation can be altered with agonists or antagonists.

[0008] In one embodiment, the present disclosure provides an optical method for detecting the effect of one or more compounds on spheroids. The method includes contacting a tissue culture plate, e.g., a plate having wells, containing one or more spheroids of human cells, such as those of uniform diameter, with one or more test compounds; and optically detecting the amount or change in oscillations in the spheroids. In one embodiment, the plate is a multi-well plate. In one embodiment, the spheroids are further contacted with a fluorescent molecule useful for detecting calcium, and the amount or change in fluorescence over time is detected. In one embodiment, the amount or change in fluorescence is detected via the amount of fluorescence peaks, the amplitude of one or more peaks, the peak interval between one or more peaks, the width of one or more peaks, or any combination thereof. In one embodiment, the spheroids include neurons. In one embodiment, the spheroids include neurons and astrocytes. In one embodiment, the spheroids include heart, liver, kidney, pancreas, lung, endothelial, or epithelial cells. In one embodiment, the spheroids include cancer cells or immortalized cells. In one embodiment, the spheroid comprises microglial cells or oligodendrocytes. In one embodiment, the spheroid comprises pericytes and endothelial cells. In one embodiment, the spheroid comprises endothelial cells, microglial cells, neuronal cells, oligodendrocytes, or any combination thereof. In one embodiment, the cells are differentiated cells. In one embodiment, the cells are progenitor cells, such as human iPSCs. In one embodiment, the progenitor cells are progenitor cells of neuronal cells, astrocytes, cardiac cells, liver cells, kidney cells, pancreatic cells, lung cells, endothelial cells, or epithelial cells. In one embodiment, the one or more spheroids have a diameter of about 500 to about 600 microns. In one embodiment, the one or more spheroids have a diameter of about 450 to about 500 microns. In one embodiment, the one or more spheroids are cultured for at least 4 to 6 weeks before contacting with one or more test compounds. In one embodiment, the fluorescent molecule comprises calcium 3, calcium 4, calcium 5, calcium 6, Fluo 3, or Fluo 4, or a combination thereof.In one embodiment, the one or more spheroids are further contacted with a cell membrane impermeable quencher. In one embodiment, the amount of change in fluorescence is compared to the fluorescence of the one or more spheroids and the fluorescent molecule but without the test compound. In one embodiment, in a multi-well plate, each well has one spheroid.

[0009] Also provided is a multi-well plate containing one or more mixed human cell spheroids per well. In one embodiment, the spheroids include neural cells and astrocytes. In one embodiment, the spheroids include cardiac, hepatic, renal, pancreatic, pulmonary, endothelial, or epithelial cells. In one embodiment, the spheroids include microglial cells or oligodendrocytes. In one embodiment, the spheroids include pericytes and endothelial cells. In one embodiment, the spheroids include endothelial cells, microglial cells, neural cells, oligodendrocytes, or any combination thereof. In one embodiment, the spheroids include precursor cells of neural cells, astrocytes, cardiac cells, liver cells, kidney cells, pancreatic cells, pulmonary cells, endothelial cells, or epithelial cells.

[0010] These and other objects and advantages of the present invention will become apparent upon reading and understanding the following detailed description. [Brief description of the drawings]

[0011] [Figure 1] FIG. 1 is an image of an exemplary 384-well microplate with one mixed cell spheroid placed in each well to demonstrate one embodiment of the present subject matter. [Diagram 2] FIG. 2 is a plot of average mixed cell spheroid size across multiple columns of a 384-well microplate in one example of an application of the present subject matter. [Diagram 3] FIG. 3 is an image of a mixed population neuronal spheroid. [Figure 4] Figure 4 is a FLIPR control plot of fluorescence produced by spheroids from a microplate well. [Diagram 5] FIG. 5 is a FLIPR data plot of spheroid control wells versus drug-exposed wells, showing the variation in response of drug-exposed versus control wells to demonstrate one application of the present subject matter. [Figure 6] FIG. 6 is a summary of the effects of various glutamatergic and GABAergic antagonists and agonists on spheroids as measured by FLIPR in one application of the present subject matter. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0012] Detailed Description The following discussion is directed to various embodiments of the present invention. One or more of these embodiments may be preferred, but the present invention is not limited to the disclosed embodiments. In addition, those skilled in the art will understand that the following description has a wide range of applications, and the discussion of any embodiment is merely an example of that embodiment, and is not intended to limit the scope of the disclosure or claims to that embodiment.

[0013] FIG. 1 is an image of an exemplary 384-well microplate with one mixed cell spheroid placed in each well, illustrating one embodiment of the present subject matter. In this example, 24 rows of 16 cells in the microplate provide 384 wells. FIG. 1 shows an actual black and white image of an entire 384-well microplate 10 in which spheroids 20 are formed in each well with a mixed population of astrocytes and neurons forming structures approximately 500 microns in diameter. The microplate may have, in one embodiment, 96, 384 or 1536 wells. Other numbers of wells are possible without departing from the scope of the present subject matter. The spheroids 20 are formed by adding individual cells to each well, which then naturally form into spheroids of different sizes depending on the number of cells added initially. The number of cells inserted into each well can range from hundreds to hundreds of thousands depending on the size of the well and the diameter of the spheroid required for the assay. In one embodiment, approximately 20,000 human iPS cells are added to the wells to form spheroids approximately 500 microns in diameter.

[0014] In Figure 1, a microBrain™ 3D plate is used to illustrate the microplate, however, it is understood that other microplates and configurations for creating multiple wells may be used.

[0015] FIG. 2 shows a plot of the diameter (i.e., "width") of spheroids 20 versus their position across 24 columns of a 384-well microwell plate. As can be seen from the data, the uniformity of diameter and size is very consistent. The ratio of astrocytes to neurons in the mixed population can range from about 5 to about 95 percent, about 10 to about 90 percent, about 20 to about 80 percent, about 40 to about 60 percent, about 60 to about 40 percent, about 80 to about 20 percent, about 90 to about 10 percent, or about 95 to about 5 percent, for example, a 50 / 50 ratio may mimic that found in the human brain. The cells used to form the spheroids can be derived from human primary cell lines, human iPScs, or engineered immortalized cell lines. Also, the spheroids are not limited to only neuronal cells, but can also be cardiac, liver, kidney, pancreatic, lung, endothelial and epithelial cells, as well as solid tumor cell lines. Other cells may be used without departing from the scope of the present subject matter.

[0016] FIG. 3 shows a black and white image of an actual mixed population neuronal spheroid 20 from an individual well in a microwell plate. What is unique about neuronal spheroids is that they self-organize into a very uniform round shape. The diameter of the spheroids can range from about 100 microns to about 10 millimeters, e.g., about 200 to about 600 microns in diameter, e.g., about 300 to about 500 microns in diameter, about 400 to about 600 microns in diameter, or about 450 to about 650 microns in diameter, or about 475 to about 525 in diameter, e.g., about 500 microns in average diameter. In this particular example, the ratio of astrocytes to neurons is about 50 / 50.

[0017] Referring to FIG. 4, the plot shows the type of data generated by the FLIPR assay on a mixed population neuronal spheroid 20 as a function of time. The parameters measured are peak count 1, peak amplitude 2, peak interval 3, and peak width 4. All of these variables may be used when interpreting the data generated by the FLIPR assay. They are indirect measurements of how the cells behave at steady state (no drug exposure) and how the drug interacts with the cells of the spheroid 20. The peaks 30 represent spontaneous fluorescent calcium oscillations generated by the spheroid in culture. Using FLIPR, data for each cell can be acquired and stored.

[0018] FIG. 5 shows the effect of the GABAergic antagonist drug Bicuculline at 50 micromolar concentration on the induction of irregular and erratic calcium uptake behavior in spheroids 20 versus control. The axes of the figure show "relative light units" and "time (seconds)". Comparison of the Bicuculline drug peaks to the control peaks shows that almost all of the measured parameters such as peak number, spacing, and height are changed. The same type of response was observed using a glutamatergic antagonist as well, but at a higher dose concentration. It should be noted that the age of the spheroids may affect drug interactions. In one embodiment, the spheroids can range in age from 2 to 52 weeks old to simulate the more mature cells found in in vivo models. In one embodiment, spheroids 20 between 5 and 10 weeks old are used. For example, older spheroids formed with neuronal cells, e.g., about 8 weeks old, allow for more synaptic connections.

[0019] Figure 6 summarizes some of the results obtained using the FLIPR assay and spheroids. The graph on the left shows the change in the number of calcium oscillation peaks generated before (control) and after exposure to well-known glutamatergic and GABAergic agonist and antagonist small molecule drug compounds used from the table on the right. As can be seen in the graph on the right, there is a significant and immediate modulation of calcium oscillations in spheroids 20 upon exposure to the drug compounds described. This type of chemically induced response could be the basis of an epileptic seizure model mimicking the one observed in humans. This 3D spheroid model could therefore be used as a high-throughput screening tool for drugs that can rescue the unstable neuronal synaptic excitation underlying, for example, seizures and other diseases.

[0020] Thus, in one embodiment, the present disclosure provides a method for performing functional assays on a mixed population of three-dimensional human cell spheroids using, in one embodiment, a fluorescent imaging plate reader. For example, highly homogenous and consistent mixed population spheroids, such as astrocyte and neuronal spheroids, may be generated from differentiated cells, such as human iPS cells. The diameter of the spheroids, in one embodiment, may range from about 500 to about 600 microns, and may be formed in the wells of a multi-well plate, such as a 384-well microplate. The spheroids are then contacted with one or more molecules, such as GABAergic and glutamatergic regulatory small molecules. The time response of calcium oscillation fluorescence intensity of the spheroids may be captured and quantified in real time, and is a measure of the cell spheroid response to drug exposure and concentration gradients. EXAMPLES

[0021] Some examples of current subjects Spheroids, for example those formed from two or more different cell types, may be prepared using any suitable medium, optionally including one or more different growth factors, and any suitable conditions. For example, spheroids formed from neurons and astrocytes may be prepared in one embodiment using one or more of the following media and / or conditions: BrainPhys™ Neuronal Medium (StemCell Tech) supplemented with 1x SM1 Neuronal Supplement (BrainPhys™ Neuronal Medium and SM1 Kit (Cat.#05792; StemCell Technologies)), 20ng / mL BDNF (cat.#78005; StemCell Technologies), 20ng / mL GDNF (cat.#78058; StemCell Technologies) and penicillin / streptomycin (cat.#SV30010; GE Healthcare Life Sciences). Cells are maintained at 37°C in an incubator with 5% CO2 and high humidity.

[0022] The subject matter allows for multiple approaches to analyze the effect of one or more compounds on spheroids, including contacting a plate (e.g., a multi-well plate with wells) containing one or more spheroids of human cells of uniform diameter with a fluorescent molecule useful for detecting calcium and one or more test compounds; and optionally detecting the amount or change in fluorescence over time, e.g., in each well. In various examples, the method detects the amount or change in fluorescence via a peak amount of fluorescence, the amplitude of one or more peaks, the peak interval between one or more peaks, the width of one or more peaks, or any combination thereof. In various examples, the aforementioned methods may include a spheroid comprising neural cells, a spheroid comprising neural cells and astrocytes, a spheroid comprising cardiac, hepatic, renal, pancreatic, lung, endothelial or epithelial cells, or a spheroid comprising cancer cells. In various examples, the spheroid may comprise multiple different cell types. In some examples, the aforementioned examples include a case where the cells are derived from human iPSCs. In some examples, the cells are differentiated cells. In some examples, the cell is a progenitor cell. In some examples using progenitor cells, the progenitor cell is a progenitor cell for a neuronal cell, an astrocyte, a cardiac cell, a hepatic cell, a renal cell, a pancreatic cell, a pulmonary cell, an endothelial cell, or an epithelial cell. In some of the foregoing examples, the cell is an immortalized cell.

[0023] In the various methods described above, the spheroids may have a diameter of about 500 to about 600 microns or a diameter of about 450 to about 500 microns. In the various methods described above, the spheroids may have been cultured for at least 6 weeks. In the various methods described above that include a fluorescent molecule, the molecule includes calcium 3, calcium 4, calcium 5, calcium 6, Fluo 3, or Fluo 4.

[0024] In one embodiment, optical assays are provided, such as functional FLIPR assays or high content high magnification optical microscopy of 3D human cell spheroids (e.g., spheroids formed from a mixed population of neurons, oligodendrocytes, microglial cells, endothelial cells, or any combination thereof).

[0025] In one embodiment, a multi-well optical assay, such as a functional FLIPR assay of 3D mixed population human cell spheroids in a multi-well format, such as 96, 384, or 1536 microplate wells, for example spheroids in round-bottom well format, is provided.

[0026] Further provided is an optical assay, e.g., functional FLIPR assay, of 3D mixed population spheroids where the spheroids in each microplate well are of uniform size, e.g., + / - 50 or + / - 25 microns in diameter. In one embodiment, the FLIPR generates real-time functional data on 3D neuronal-based cell spheroids that are highly consistent within a microplate, e.g., well-to-well, and plate-to-plate.

[0027] In one embodiment, the present disclosure provides optical assays including functional FLIPR assays of 3D mixed population spheroids responding in real time to agonist or antagonist drug exposure.

[0028] In one embodiment, the present disclosure provides optical assays, such as functional FLIPR assays, of 3D mixed population spheroids derived from human primary cells, iPSc, differentiated cells, or various immortalized human cell lines.

[0029] In various of the above methods, the method further includes contacting the well with a cell membrane-impermeable quencher. In any of the above methods, the change in fluorescence can be compared to the fluorescence in a well containing the spheroids and the fluorescent molecule but no test compound.

[0030] Those skilled in the art will recognize that other examples and variations are possible without departing from the scope of the present subject matter.

[0031] The above description is intended to illustrate the principles and various embodiments of the present invention. In the foregoing specification, the invention has been described in connection with certain preferred embodiments thereof, and many details have been described for purposes of illustration, but it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments, and that some of the details herein may be significantly modified without departing from the basic principles of the invention. Thus, numerous variations and modifications will be apparent to those skilled in the art once the above disclosure is fully appreciated. For example, the present invention is not limited to neural cells or mixed populations of neural cells. The present invention can be applied to all organ types found in humans, such as heart, lung, liver, kidney, colon, pancreas, and cancer mixed population cell spheroids, to name a few. It is intended that the following claims be construed to embrace all such variations and modifications.

Claims

1. 1. An optical method for detecting the effect of one or more compounds on a spheroid, comprising: contacting one or more spheroids of uniform diameter human cells with one or more test compounds; and optically detecting an amount or change in one or more vibrations of said spheroids; A method comprising:

2. 10. The method of claim 1, wherein the one or more spheroids are in a well of a multi-well plate.

3. The method of claim 2, wherein each well contains one spheroid.

4. 4. The method of claim 2 or 3, wherein the wells are further contacted with a fluorescent molecule useful for detecting calcium, and the amount or change in fluorescence over time is detected in one or more wells.

5. 5. The method of claim 4, wherein the amount or change in fluorescence is detected by detecting an amount of fluorescence peaks, an amplitude of one or more peaks, a peak spacing between one or more peaks, a width of one or more peaks, or any combination thereof.

6. The method of any one of claims 1 to 5, wherein the one or more spheroids comprise neural cells.

7. The method of any one of claims 1 to 5, wherein the one or more spheroids comprise neurons and astrocytes.

8. The method of any one of claims 1 to 7, wherein the one or more spheroids comprise cardiac, hepatic, renal, pancreatic, lung, endothelial or epithelial cells.

9. The method of any one of claims 1 to 8, wherein the one or more spheroids comprise cancer cells or immortalized cells.

10. The method of any one of claims 1 to 9, wherein the one or more spheroids comprise microglial cells or oligodendrocytes.

11. The method of any one of claims 1 to 10, wherein the one or more spheroids comprise pericytes and endothelial cells.

12. The method of any one of claims 1 to 11, wherein the one or more spheroids comprise endothelial cells, microglial cells, neuronal cells, oligodendrocyte cells, or any combination thereof.

13. The method of any one of claims 1 to 12, wherein the cells are progenitor cells.

14. 14. The method of claim 13, wherein the progenitor cells are progenitor cells for neural cells, astrocytes, cardiac cells, liver cells, kidney cells, pancreatic cells, lung cells, endothelial cells, or epithelial cells.

15. 15. The method of any one of claims 1 to 14, wherein the one or more spheroids have a diameter of about 500 to about 600 microns.

16. 15. The method of any one of claims 1 to 14, wherein the one or more spheroids have a diameter of about 450 to about 500 microns.

17. The method of any one of claims 1 to 16, wherein the one or more spheroids are cultured for at least 4 to 6 weeks before contacting with the one or more test compounds.

18. The method of any one of claims 3 to 17, wherein the fluorescent molecule comprises calcium 3, calcium 4, calcium 5, calcium 6, Fluo 3, or Fluo 4.

19. The method of any one of claims 3 to 18, further comprising contacting the well with a cell membrane-impermeable quencher.

20. The method according to any one of claims 3 to 19, wherein the amount of change in fluorescence is compared to the fluorescence in a well containing spheroids and fluorescent molecules but no test compound.

21. A multi-well plate containing one or more mixed human cell spheroids per well.

22. 22. The plate of claim 21 , wherein the one or more spheroids comprise neurons and astrocytes.

23. 23. The plate of claim 21 or 22, wherein the one or more spheroids comprise cardiac, hepatic, renal, pancreatic, lung, endothelial or epithelial cells.

24. The plate of any one of claims 21 to 23, wherein the one or more spheroids comprise microglial cells or oligodendrocytes.

25. The plate of any one of claims 21 to 24, wherein the one or more spheroids comprise pericytes and endothelial cells.

26. The plate of any one of claims 21 to 25, wherein the one or more spheroids comprise endothelial cells, microglial cells, neuronal cells, oligodendrocyte cells, or any combination thereof.

27. 27. The plate of any one of claims 21 to 26, wherein the one or more spheroids comprise progenitor cells of neurons, astrocytes, cardiac cells, liver cells, kidney cells, pancreatic cells, lung cells, endothelial cells, or epithelial cells.

28. The plate of any one of claims 21 to 27, wherein the wells contain spheroids formed from different cells.

Citation Information

Patent Citations

  • Device, method, and program for supporting evaluation of influence of medicine onto cardiac muscle

    JP2017015497A

  • Cardiac or vascular tissue spheroid

    WO2014141528A1